Lymphedema Screening (LymphScreen)
Screening for Lymphedema
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mads G Jørgensen, MD
- Phone Number: +45 29210114
- Email: Mads.Gustaf.Jorgensen@rsyd.dk
Study Locations
-
-
-
Odense, Denmark, 5000
- Recruiting
- Department of plastic and reconstructive Surgery
-
Contact:
- Mads G Jørgensen, MD
- Email: Mads.Gustaf.Jorgensen@rsyd.dk
-
Contact:
- Jens A Sørensen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Previous breast cancer treated with axillary lymph node dissection
- No recurrence
- Understand the study
- Can talk, read and understand Danish
Exclusion Criteria:
- Pregnant or breast feeding
- Lymph node dissection from other basins
- Psychiatric disorder
- Not possible to perform indocyanine green lymphangiography
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OTHER: Breast cancer patients with lymphedema
|
centimeter and volume criterias
Presence of dermal backflow
7.5 and 10 L-DEX criterias
using lymph-icf, DASH and SF-36 questionnaires
|
|
OTHER: Breast cancer patients without lymphedema
|
centimeter and volume criterias
Presence of dermal backflow
7.5 and 10 L-DEX criterias
using lymph-icf, DASH and SF-36 questionnaires
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sensitivity, specificy, NPV and PPV
Time Frame: through study completion, approximately 1 year
|
diagnosotic statistics of lymphedema measurements
|
through study completion, approximately 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- S-20200094
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.